Posted by Michael Wonder on 27 Nov 2018
HighTide Therapeutics receives fast track designation from the U.S. FDA for HTD1801 treating non-alcoholic steatohepatitis
27 November 2018 - HighTide Therapeutics announced that the U.S. FDA has granted fast track designation to its investigational new drug, HTD1801, for the treatment of patients with non-alcoholic steatohepatitis.
HighTide completed a first in human study of HTD1801 in healthy volunteers. A multi-center Phase 2 trial in adult patients with patients with non-alcoholic steatohepatitis (NASH) is scheduled to enrol soon in the United States.
